The metastatic breast cancer treatment market size has grown rapidly in recent years. It will grow from $20.08 billion in 2024 to $22.41 billion in 2025 at a compound annual growth rate (CAGR) of 11.6%. The growth in the historic period can be attributed to advancements in systemic therapies, clinical trial success, improved diagnostic tools, patient advocacy and education.
The metastatic breast cancer treatment market size is expected to see rapid growth in the next few years. It will grow to $34.69 billion in 2029 at a compound annual growth rate (CAGR) of 11.5%. The growth in the forecast period can be attributed to targeted therapies advancements, personalized medicine trends, rising incidence rates, global access to innovative therapies. Major trends in the forecast period include liquid biopsy for monitoring, patient-centric approaches, enhanced supportive care, expanded access to innovative therapies, collaborative research initiatives.
The anticipated rise in breast cancer prevalence is set to drive the growth of the metastatic breast cancer treatment market in the foreseeable future. Breast cancer, a type of cancer originating in the cells of the breast, develops as abnormal cells undergo uncontrolled growth, forming tumors. This occurrence is influenced by genetic factors, hormonal imbalances, lifestyle, and environmental elements. Metastatic breast cancer treatment contributes to managing the prevalence of breast cancer, enhancing outcomes, and improving the quality of life for individuals facing advanced-stage disease. As per a September 2023 report from the American Cancer Society, approximately 297,790 women are expected to be diagnosed with invasive breast cancer in the same year, with an additional 55,720 new cases of ductal carcinoma in situ (DCIS) projected. The report also estimates that around 43,700 women will succumb to breast cancer in 2023. Consequently, the increasing prevalence of breast cancer stands as a driving force behind the growth of the metastatic breast cancer treatment market.
The surge in the geriatric population is poised to bolster the growth of the metastatic breast cancer treatment market. The geriatric population, typically defined as individuals aged 65 or older, is witnessing an upward trend, contributing significantly to the demand for metastatic breast cancer treatments. With age being a notable risk factor for developing metastatic breast cancer, addressing the unique needs of this demographic becomes crucial for sustained market growth. As indicated in an October 2022 report from the World Health Organization (WHO), it is projected that by 2030, one out of every six individuals globally will be 60 years old or older. The estimate further predicts that by 2050, there will be 2.1 billion people worldwide falling into this age bracket. Hence, the increase in the geriatric population emerges as a key driver for the growth of the metastatic breast cancer treatment market.
The introduction of advanced therapeutic remedies is a prominent trend gaining traction in the metastatic breast cancer treatment market. Major companies in this market are actively advancing therapeutic remedies as part of their strategy to maintain a competitive position. An example is BDR Pharmaceuticals Internationals Pvt. Ltd., an India-based pharmaceutical company that launched Palbociclib, branded as 'BDPALBO' in India. BDPALBO, a generic version of palbociclib, offers a cost-effective treatment option for patients diagnosed with metastatic breast cancer.
Innovation in product development, particularly monoclonal antibodies (mAbs), is a key focus for major companies operating in the metastatic breast cancer treatment market. Monoclonal antibodies, laboratory-produced molecules mimicking the immune system's ability to combat pathogens, are gaining prominence. Roche Pharma, a Switzerland-based pharmaceutical company, introduced PHESGO in India in May 2022. PHESGO, a groundbreaking formulation, combines two monoclonal antibodies, Perjeta (pertuzumab) and Herceptin (trastuzumab), along with hyaluronidase, providing a streamlined treatment approach for both early and metastatic HER2-positive breast cancer. This innovation aims to enhance treatment efficiency and patient convenience, incorporating the benefits of multiple monoclonal antibodies into a more accessible and patient-friendly delivery method.
In April 2023, Pfizer Inc., a US-based biotechnology and pharmaceutical company, acquired Seagen Inc. for $43 billion. This acquisition enhances Pfizer’s oncology portfolio by incorporating antibody-drug conjugate (ADC) technology for the development of drug programs. Seagen Inc., a US-based biotechnology company, is known for its contributions to metastatic triple-negative breast cancer treatment.
Major companies operating in the metastatic breast cancer treatment market include Pfizer Inc., AstraZeneca plc, Novartis AG, Eli Lilly & Co., Merck & Co. Inc., Johnson & Johnson Services Inc., Sun Pharmaceutical Industries Ltd., F. Hoffmann-La Roche AG, Bayer Aktiengesellschaft., Bristol-Myers Squibb Company, Boehringer Ingelheim Gmbh, Aslan Pharmaceuticals Pte. Ltd., AbbVie Inc., Eisai Co. ltd., Seattle Genetics Inc., Immunomedics Inc., Genentech Inc., MacroGenics Inc., Daiichi Sankyo Company Lmited, Takeda Pharmaceutical Company Lmited, Celgene Corporation, Exelixis Inc., Array BioPharma Inc., Athenex Inc., Clovis Oncology Inc., Cyclacel Pharmaceuticals Inc., Immunovative Therapies Ltd., Inovio Pharmaceuticals Inc., Karyopharm Therapeutics Inc., Mersana Therapeutics Inc., Nektar Therapeutics Inc.
North America was the largest region in the metastatic breast cancer treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the global metastatic breast cancer treatment market during the forecast period. The regions covered in the metastatic breast cancer treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the metastatic breast cancer treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Metastatic breast cancer treatment involves medical interventions and therapies aimed at managing breast cancer that has spread (metastasized) from the breast to other parts of the body. The primary objectives of treating metastatic breast cancer are to maximize the patient's survival duration with the disease.
The main types of metastatic breast cancer treatment include chemotherapy, radiation therapy, biologic-targeted therapy, breast surgery, and hormone therapy. Chemotherapy utilizes drugs designed to kill or inhibit the growth of rapidly dividing cells, including cancer cells. It achieves this by targeting the DNA or essential processes of these cells. In the context of metastatic breast cancer treatment, chemotherapy aims to kill or control cancer cells throughout the body, utilizing specific drugs that circulate in the bloodstream. Various types of molecules, such as monoclonal antibodies, peptides, polymers, small molecules, and gene therapy, are administered through oral or parenteral routes by healthcare facilities such as hospitals, clinics, ambulatory surgical centers, and other end-users.
The metastatic breast cancer treatment market research report is one of a series of new reports that provides metastatic breast cancer treatment market statistics, including the metastatic breast cancer treatment industry global market size, regional shares, competitors with a metastatic breast cancer treatment market share, detailed metastatic breast cancer treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the metastatic breast cancer treatment industry. This metastatic breast cancer treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The metastatic breast cancer treatment market includes revenues earned by entities by immunotherapy, and targeted therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The metastatic breast cancer treatment market size is expected to see rapid growth in the next few years. It will grow to $34.69 billion in 2029 at a compound annual growth rate (CAGR) of 11.5%. The growth in the forecast period can be attributed to targeted therapies advancements, personalized medicine trends, rising incidence rates, global access to innovative therapies. Major trends in the forecast period include liquid biopsy for monitoring, patient-centric approaches, enhanced supportive care, expanded access to innovative therapies, collaborative research initiatives.
The anticipated rise in breast cancer prevalence is set to drive the growth of the metastatic breast cancer treatment market in the foreseeable future. Breast cancer, a type of cancer originating in the cells of the breast, develops as abnormal cells undergo uncontrolled growth, forming tumors. This occurrence is influenced by genetic factors, hormonal imbalances, lifestyle, and environmental elements. Metastatic breast cancer treatment contributes to managing the prevalence of breast cancer, enhancing outcomes, and improving the quality of life for individuals facing advanced-stage disease. As per a September 2023 report from the American Cancer Society, approximately 297,790 women are expected to be diagnosed with invasive breast cancer in the same year, with an additional 55,720 new cases of ductal carcinoma in situ (DCIS) projected. The report also estimates that around 43,700 women will succumb to breast cancer in 2023. Consequently, the increasing prevalence of breast cancer stands as a driving force behind the growth of the metastatic breast cancer treatment market.
The surge in the geriatric population is poised to bolster the growth of the metastatic breast cancer treatment market. The geriatric population, typically defined as individuals aged 65 or older, is witnessing an upward trend, contributing significantly to the demand for metastatic breast cancer treatments. With age being a notable risk factor for developing metastatic breast cancer, addressing the unique needs of this demographic becomes crucial for sustained market growth. As indicated in an October 2022 report from the World Health Organization (WHO), it is projected that by 2030, one out of every six individuals globally will be 60 years old or older. The estimate further predicts that by 2050, there will be 2.1 billion people worldwide falling into this age bracket. Hence, the increase in the geriatric population emerges as a key driver for the growth of the metastatic breast cancer treatment market.
The introduction of advanced therapeutic remedies is a prominent trend gaining traction in the metastatic breast cancer treatment market. Major companies in this market are actively advancing therapeutic remedies as part of their strategy to maintain a competitive position. An example is BDR Pharmaceuticals Internationals Pvt. Ltd., an India-based pharmaceutical company that launched Palbociclib, branded as 'BDPALBO' in India. BDPALBO, a generic version of palbociclib, offers a cost-effective treatment option for patients diagnosed with metastatic breast cancer.
Innovation in product development, particularly monoclonal antibodies (mAbs), is a key focus for major companies operating in the metastatic breast cancer treatment market. Monoclonal antibodies, laboratory-produced molecules mimicking the immune system's ability to combat pathogens, are gaining prominence. Roche Pharma, a Switzerland-based pharmaceutical company, introduced PHESGO in India in May 2022. PHESGO, a groundbreaking formulation, combines two monoclonal antibodies, Perjeta (pertuzumab) and Herceptin (trastuzumab), along with hyaluronidase, providing a streamlined treatment approach for both early and metastatic HER2-positive breast cancer. This innovation aims to enhance treatment efficiency and patient convenience, incorporating the benefits of multiple monoclonal antibodies into a more accessible and patient-friendly delivery method.
In April 2023, Pfizer Inc., a US-based biotechnology and pharmaceutical company, acquired Seagen Inc. for $43 billion. This acquisition enhances Pfizer’s oncology portfolio by incorporating antibody-drug conjugate (ADC) technology for the development of drug programs. Seagen Inc., a US-based biotechnology company, is known for its contributions to metastatic triple-negative breast cancer treatment.
Major companies operating in the metastatic breast cancer treatment market include Pfizer Inc., AstraZeneca plc, Novartis AG, Eli Lilly & Co., Merck & Co. Inc., Johnson & Johnson Services Inc., Sun Pharmaceutical Industries Ltd., F. Hoffmann-La Roche AG, Bayer Aktiengesellschaft., Bristol-Myers Squibb Company, Boehringer Ingelheim Gmbh, Aslan Pharmaceuticals Pte. Ltd., AbbVie Inc., Eisai Co. ltd., Seattle Genetics Inc., Immunomedics Inc., Genentech Inc., MacroGenics Inc., Daiichi Sankyo Company Lmited, Takeda Pharmaceutical Company Lmited, Celgene Corporation, Exelixis Inc., Array BioPharma Inc., Athenex Inc., Clovis Oncology Inc., Cyclacel Pharmaceuticals Inc., Immunovative Therapies Ltd., Inovio Pharmaceuticals Inc., Karyopharm Therapeutics Inc., Mersana Therapeutics Inc., Nektar Therapeutics Inc.
North America was the largest region in the metastatic breast cancer treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the global metastatic breast cancer treatment market during the forecast period. The regions covered in the metastatic breast cancer treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the metastatic breast cancer treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Metastatic breast cancer treatment involves medical interventions and therapies aimed at managing breast cancer that has spread (metastasized) from the breast to other parts of the body. The primary objectives of treating metastatic breast cancer are to maximize the patient's survival duration with the disease.
The main types of metastatic breast cancer treatment include chemotherapy, radiation therapy, biologic-targeted therapy, breast surgery, and hormone therapy. Chemotherapy utilizes drugs designed to kill or inhibit the growth of rapidly dividing cells, including cancer cells. It achieves this by targeting the DNA or essential processes of these cells. In the context of metastatic breast cancer treatment, chemotherapy aims to kill or control cancer cells throughout the body, utilizing specific drugs that circulate in the bloodstream. Various types of molecules, such as monoclonal antibodies, peptides, polymers, small molecules, and gene therapy, are administered through oral or parenteral routes by healthcare facilities such as hospitals, clinics, ambulatory surgical centers, and other end-users.
The metastatic breast cancer treatment market research report is one of a series of new reports that provides metastatic breast cancer treatment market statistics, including the metastatic breast cancer treatment industry global market size, regional shares, competitors with a metastatic breast cancer treatment market share, detailed metastatic breast cancer treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the metastatic breast cancer treatment industry. This metastatic breast cancer treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The metastatic breast cancer treatment market includes revenues earned by entities by immunotherapy, and targeted therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Metastatic Breast Cancer Treatment Market Characteristics3. Metastatic Breast Cancer Treatment Market Trends and Strategies4. Metastatic Breast Cancer Treatment Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid and Recovery on the Market32. Global Metastatic Breast Cancer Treatment Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Metastatic Breast Cancer Treatment Market34. Recent Developments in the Metastatic Breast Cancer Treatment Market
5. Global Metastatic Breast Cancer Treatment Growth Analysis and Strategic Analysis Framework
6. Metastatic Breast Cancer Treatment Market Segmentation
7. Metastatic Breast Cancer Treatment Market Regional and Country Analysis
8. Asia-Pacific Metastatic Breast Cancer Treatment Market
9. China Metastatic Breast Cancer Treatment Market
10. India Metastatic Breast Cancer Treatment Market
11. Japan Metastatic Breast Cancer Treatment Market
12. Australia Metastatic Breast Cancer Treatment Market
13. Indonesia Metastatic Breast Cancer Treatment Market
14. South Korea Metastatic Breast Cancer Treatment Market
15. Western Europe Metastatic Breast Cancer Treatment Market
16. UK Metastatic Breast Cancer Treatment Market
17. Germany Metastatic Breast Cancer Treatment Market
18. France Metastatic Breast Cancer Treatment Market
19. Italy Metastatic Breast Cancer Treatment Market
20. Spain Metastatic Breast Cancer Treatment Market
21. Eastern Europe Metastatic Breast Cancer Treatment Market
22. Russia Metastatic Breast Cancer Treatment Market
23. North America Metastatic Breast Cancer Treatment Market
24. USA Metastatic Breast Cancer Treatment Market
25. Canada Metastatic Breast Cancer Treatment Market
26. South America Metastatic Breast Cancer Treatment Market
27. Brazil Metastatic Breast Cancer Treatment Market
28. Middle East Metastatic Breast Cancer Treatment Market
29. Africa Metastatic Breast Cancer Treatment Market
30. Metastatic Breast Cancer Treatment Market Competitive Landscape and Company Profiles
31. Metastatic Breast Cancer Treatment Market Other Major and Innovative Companies
35. Metastatic Breast Cancer Treatment Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Metastatic Breast Cancer Treatment Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on metastatic breast cancer treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for metastatic breast cancer treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The metastatic breast cancer treatment market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Therapy Type: Chemotherapy; Radiation Therapy; Biologic Targeted Therapy; Breast Surgery; Hormone Therapy2) By Molecule Type: Monoclonal Antibody; Peptides; Polymer; Small Molecule; Gene Therapy
3) By Route of Administration: Oral; Parenteral
4) By End-User: Hospitals; Clinics; Ambulatory Surgical Centers; Other End-Users
Subsegments:
1) By Chemotherapy: Anthracyclines; Taxanes; Antimetabolites; Platinum Agents2) By Radiation Therapy: External Beam Radiation; Stereotactic Radiosurgery; Brachytherapy
3) By Biologic Targeted Therapy: HER2-Targeted Therapy; CDK4 or 6 Inhibitors; PARP Inhibitors; PI3K Inhibitors
4) By Breast Surgery: Lumpectomy; Mastectomy; Sentinel Lymph Node Biopsy; Reconstructive Surgery
5) By Hormone Therapy: Selective Estrogen Receptor Modulators (SERMs); Aromatase Inhibitors; Estrogen Receptor Downregulators (ERDs)
Key Companies Mentioned: Pfizer Inc.; AstraZeneca plc; Novartis AG; Eli Lilly & Co.; Merck & Co. Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Pfizer Inc.
- AstraZeneca plc
- Novartis AG
- Eli Lilly & Co.
- Merck & Co. Inc.
- Johnson & Johnson Services Inc.
- Sun Pharmaceutical Industries Ltd.
- F. Hoffmann-La Roche AG
- Bayer Aktiengesellschaft.
- Bristol-Myers Squibb Company
- Boehringer Ingelheim Gmbh
- Aslan Pharmaceuticals Pte. Ltd.
- AbbVie Inc.
- Eisai Co. ltd.
- Seattle Genetics Inc.
- Immunomedics Inc.
- Genentech Inc.
- MacroGenics Inc.
- Daiichi Sankyo Company Lmited
- Takeda Pharmaceutical Company Lmited
- Celgene Corporation
- Exelixis Inc.
- Array BioPharma Inc.
- Athenex Inc.
- Clovis Oncology Inc.
- Cyclacel Pharmaceuticals Inc.
- Immunovative Therapies Ltd.
- Inovio Pharmaceuticals Inc.
- Karyopharm Therapeutics Inc.
- Mersana Therapeutics Inc.
- Nektar Therapeutics Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | February 2025 |
| Forecast Period | 2025 - 2029 |
| Estimated Market Value ( USD | $ 22.41 Billion |
| Forecasted Market Value ( USD | $ 34.69 Billion |
| Compound Annual Growth Rate | 11.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 31 |
